is saxenda a glp 1 drug Saxenda© – New Treatment for Obesity Article » ProAct

doi:10.1007/s00125-008-1149-y Buteau J

Although clinical studies have not demonstrated overt systemic depletion of NAD(P) during GLP-1RA therapy, sustained reductions in nutrient inflow may influence precursor availability and turnover kinetics, particularly in metabolically stressed populations

Pregnancy and breastfeeding : GLP-1 receptor agonists are not recommended during pregnancy

461 GLP-1RAs can suppress the activation of nuclear factor-kappa B (NF-B), a key transcription factor involved in the regulation of inflammatory processes

Neural Regener Res (2020) 15(7):13339

Effects on weight reduction may contribute to improvements in metabolic function